Parnassus Investments Has Trimmed Gilead Sciences INC (GILD) Position by $62.31 Million

Marco Green
January 2, 2018

The institutional investor held 263,309 shares of the health care company at the end of 2017Q3, valued at $21.33M, up from 237,487 at the end of the previous reported quarter. Moreover, Winch Advisory Service has 0.01% invested in Gilead Sciences, Inc. The stock decreased 1.16% or $0.84 during the last trading session, reaching $71.64. Shares Dropping -1.16% to trade at $71.64. (NASDAQ:GILD) shares were sold by Washington Robin L. MARTIN JOHN C also sold $6.05 million worth of Gilead Sciences, Inc. It has underperformed by 38.50% the S&P500. (SLAB) by 23.16% based on its latest 2017Q3 regulatory filing with the SEC. Birch Hill Investment Advisors Llc bought 28,890 shares as the company's stock declined 6.00% while stock markets rallied.

Sentinel Trust Company Lba increased Facebook Inc Cl A (NASDAQ:FB) stake by 14,150 shares to 16,019 valued at $2.74M in 2017Q3. Nbt Bank N A who had been investing in Gilead Sciences Inc for a number of months, seems to be bullish on the $95.79B market cap company. The stock decreased 0.94% or $0.28 during the last trading session, reaching $29.52. About 163,240 shares traded or 30.78% up from the average. Bank of America Corporation (NYSE:BAC) has risen 58.64% since January 2, 2017 and is uptrending. It has outperformed by 0.96% the S&P500.

Investors sentiment increased to 1.03 in 2017 Q3. Its up 0.10, from 0.93 in 2017Q2. Hollencrest Secs reported 12,000 shares or 0.02% of all its holdings. 117 funds opened positions while 547 raised stakes. Mason Street Limited Liability invested in 0.85% or 1.36M shares. (NASDAQ:GILD). Cap Guardian owns 0.11% invested in Gilead Sciences, Inc. Livforsakringsbolaget Skandia Omsesidigt stated it has 110,637 shares or 0.8% of all its holdings. Sentinel Asset Mgmt, Vermont-based fund reported 332,786 shares. Jpmorgan Chase & Com accumulated 0% or 245,495 shares. Picton Mahoney Asset Mgmt invested in 717,900 shares or 1.37% of the stock. Bridgeway Management reported 105,418 shares. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company's stock worth $6,571,355,000 after purchasing an additional 2,148,697 shares during the last quarter. Commonwealth Equity Services Inc, a Massachusetts-based fund reported 110,063 shares. Bruce holds 0.37% of its portfolio in Ashland Global Holdings Inc. Bnp Paribas Arbitrage Sa has 2.17M shares. Pictet Asset Management Ltd. owned approximately 0.27% of Gilead Sciences worth $280,494,000 as of its most recent SEC filing. Royal Natl Bank Of Canada has invested 0% in Orthofix International N.V. (NASDAQ:OFIX). Alliancebernstein LP invested 0% in TG Therapeutics, Inc. (NYSE:HON) for 13,631 shares.

Analysts await Silicon Laboratories Inc. They expect $1.67 earnings per share, down 36.74% or $0.97 from last year's $2.64 per share. GILD's profit will be $2.18 billion for 10.72 P/E if the $1.67 EPS becomes a reality. Morgan Stanley reissued an "equal weight" rating and issued a $83.00 target price (up previously from $77.00) on shares of Gilead Sciences in a research report on Friday, October 6th. Orthofix International had 9 analyst reports since August 18, 2015 according to SRatingsIntel. Jefferies has "Buy" rating and $2300 target. Therefore 81% are positive. The third largest holder is State Street Corp, which now holds $3.97 billion worth of this stock and that ownership represents almost 4.22% of its market capitalization. The firm earned "Neutral" rating on Friday, December 18 by Atlantic Securities. Berenberg Bank set a $96.00 price target on shares of Gilead Sciences and gave the stock a "buy" rating in a research report on Thursday, October 19th. Citigroup initiated Gilead Sciences, Inc. Jefferies has "Hold" rating and $80 target. The firm earned "Buy" rating on Thursday, August 24 by Stifel Nicolaus. Jefferies maintained the stock with "Buy" rating in Sunday, September 10 report. M Partners upgraded the shares of SLAB in report on Thursday, October 27 to "Buy" rating. (NASDAQ:GILD) rating on Tuesday, July 11. (NASDAQ:SLAB) on Tuesday, September 19. (NYSE:CAH) by 225,000 shares to 1.40M shares, valued at $93.69 million in 2017Q3, according to the filing. Shareholders of record on Friday, December 15th were issued a $0.52 dividend. Deily Linnet F sold $601,514 worth of stock. Another trade for 850 shares valued at $107,653 was sold by GLICKMAN DANIEL R. Pankau Ronald A. sold $37,434 worth of stock or 300 shares.

Since August 1, 2017, it had 0 insider purchases, and 9 selling transactions for $36.34 million activity. California-based Nelson Roberts Investment Advsrs Lc has invested 2.04% in Gilead Sciences, Inc. (NASDAQ:GILD). 187,874 were accumulated by Creative Planning.

Recent insider trends for Gilead Sciences, Inc. The insider Meyers James R sold 60,000 shares worth $4.99M. Its down 0.33, from 0.33 in 2017Q2. (NASDAQ:GILD) by some 96,345,171 shares, 752 decreased positions by 68,563,328 and 170 held positions by 847,123,413.

Other institutional investors and hedge funds also recently made changes to their positions in the company. The biopharmaceutical company reported $2.27 earnings per share for the quarter, topping analysts' consensus estimates of $2.13 by $0.14. (NASDAQ:GILD). Fayez Sarofim holds 0.11% in Gilead Sciences, Inc. (NASDAQ:GILD) for 696,622 shares. Kepos Limited Partnership reported 0.54% stake. Vanguard Group Inc. grew its position in Gilead Sciences by 2.4% during the 2nd quarter. (NASDAQ:GILD). Balyasny Asset Mngmt Ltd Liability holds 0.06% in Gilead Sciences, Inc. (NASDAQ:GILD) for 401,836 shares. Welch And Forbes Limited Com reported 0.34% in Gilead Sciences, Inc. (NASDAQ:GILD) news were published by: Fool.com which released: "Is Gilead Sciences, Inc. a Buy?" on December 10, 2017, also Seekingalpha.com with their article: "Gilead's 2018 And Beyond - Buckle Up For A New Gilead" published on December 22, 2017, Fool.com published: "Why Gilead Sciences Stock Should Be Avoided in 2018" on December 29, 2017.

Investors sentiment increased to 1.03 in 2017 Q3. Fruth Inv Mgmt holds 3,200 shares. The stock of Gilead Sciences, Inc. This showed a surprise of 6.6% in the last quarter earnings. Asset Strategies Inc holds 70,826 shares. Cincinnati Insur stated it has 76,000 shares. Foundation reported 232,589 shares.

Hodges Capital Management Inc, which manages about $2.29 billion and $1.48 billion US Long portfolio, decreased its stake in United States Steel Corp (NYSE:X) by 32,535 shares to 1.56 million shares, valued at $39.93 million in 2017Q3, according to the filing.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER